Standard BioTools to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Standard BioTools (NASDAQ: LAB) has announced its management team's participation in two major investor conferences in November 2024. President and CEO Michael Egholm, PhD, will deliver corporate presentations at the UBS Global Healthcare Conference on November 12 at 1:15 p.m. PT and at the Jefferies London Healthcare Conference on November 19 at 8:30 a.m. GMT. The presentations will be webcast live on the company's Investor Relations page, with recordings archived at investors.standardbio.com.

News Market Reaction – LAB

+4.26%

1 alert

+4.26% News Effect

On the day this news was published, LAB gained 4.26%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November:

• UBS Global Healthcare Conference on November 12^th, 2024
  President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m. PT
• Jefferies London Healthcare Conference on November 19^th – 21^st, 2024
  President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 19, 2024, at 8:30 a.m. GMT

Available presentations will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook^®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Investor Contact

David Holmes
Gilmartin Group LLC
ir@standardbio.com

FAQ

When is Standard BioTools (LAB) presenting at the UBS Global Healthcare Conference 2024?

Standard BioTools (LAB) will present at the UBS Global Healthcare Conference on November 12, 2024, at 1:15 p.m. PT.

What investor conferences is Standard BioTools (LAB) attending in November 2024?

Standard BioTools (LAB) is attending two conferences: the UBS Global Healthcare Conference on November 12 and the Jefferies London Healthcare Conference on November 19-21, 2024.

Where can I watch Standard BioTools (LAB) investor conference presentations?

The presentations will be webcast live on Standard BioTools' Investor Relations page under Events & Presentations, with recordings archived at investors.standardbio.com.

What time is Standard BioTools (LAB) presenting at the Jefferies London Healthcare Conference?

Standard BioTools (LAB) will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:30 a.m. GMT.